An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma

Lymphoma, Non Hodgkin Clinical Trial

Official title:

The National Lymphocare Study: An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00097565
• Other study ID #: U2963n
• Status: Completed
• Phase: N/A
• First received: November 24, 2004
• Last updated: March 21, 2017
• Start date: March 2004
• Est. completion date: March 2014

Study information

• Verified date: March 2017
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, observational, longitudinal, multicenter study of patients with newly diagnosed follicular Non Hodgkin's Lymphoma (NHL) designed to delineate differences in clinical outcome by comparing the effectiveness and safety of common treatment regimens.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2740
• Est. completion date: March 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed Informed Consent Form (unless the Institutional Review Board [IRB] has granted a waiver of consent)

• Signed Authorization for the Use and Disclosure of Health Information document

• Age =18 years

• Histologic documentation of follicular NHL, according to Revised European-American Lymphoma (REAL) classification system, as assessed by the local pathologist and treating physician

• Initial diagnosis of follicular B-cell NHL within 6 months prior to enrollment

• Availability of cancer-specific historical data points in the patient's medical records

Exclusion Criteria:

• Other indolent or histologic NHL subtypes

• Diagnosis of lymphoma > 6 months prior to enrollment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Follicular
• Lymphoma, Non Hodgkin
• Lymphoma, Non-Hodgkin

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Genentech, Inc.